Dear Colleagues,

The management of patients with migraine is often unsatisfactory because available acute and preventive therapies are either ineffective or poorly tolerated.  Chronic migraine is a very invalidating disease and research in the last year is growing up. Indeed, with the advent of new approaches, including botulin toxin, monoclonal antibodies and neuromodulation, clinicians have more weapons to fight this relevant problem.  This special issue is aimed at investigating the importance of migraine as a common but still undertreated and overlooked problem.

Papers dealing with the understanding of the pathogenetic mechanism subtending migraine, as well as new treatments and patents, are particularly welcomed.  They may include either animal models or clinical studies, with regard to prospective cohort studies or randomized clinical trials. 
Ethical, legal and socio-relational concerns, including sexual dysfunction, are also of interest to the special issue.

Prof. Dr. Rocco Salvatore Calabrò

Guest Editor

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1900 USD. Submitted manuscripts should be well formatted in good English.